PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19235590-1	2009	We hypothesized that co-targeting the epidermal growth factor receptor (EGFR) and Src with the EGFR inhibitor gefitinib and the Src inhibitor AZD0530 would increase growth inhibition and impede migration.	saracatinib	142-149	epidermal growth factor receptor	Homo sapiens	38-70	
19451593-8	2009	Combined anastrozole/AZD0530 reduced drug resistance and showed greater antitumor efficacy in vivo with greater Src and epidermal growth factor receptor inhibition and a greater increase in p27 and reduction of Ki-67 than either drug alone, supporting further evaluation of these putative predictors of response to combined Src/aromatase inhibition in vivo.	saracatinib	21-28	epidermal growth factor receptor	Homo sapiens	120-152	
19235590-1	2009	We hypothesized that co-targeting the epidermal growth factor receptor (EGFR) and Src with the EGFR inhibitor gefitinib and the Src inhibitor AZD0530 would increase growth inhibition and impede migration.	saracatinib	142-149	epidermal growth factor receptor	Homo sapiens	72-76	
34158343-6	2021	Additionally, AZD0530 was shown to inhibit the radiation-induced EGFR/PI3K/AKT pathway which in known to promote and regulate radioresistance and survival of GBM cells by radiation.	saracatinib	14-21	epidermal growth factor receptor	Homo sapiens	65-69	
17918184-7	2008	Treatment with the dual specific Abl/c-Src kinase inhibitor AZD0530 significantly reduces the growth inhibitory effect of high EGF concentrations, signifying that EGFR induced IRF-1 is responsible for the observed growth inhibition.	saracatinib	60-67	epidermal growth factor receptor	Homo sapiens	163-167	
23144237-9	2013	Saracatinib enhanced the effects of lapatinib, an EGFR/HER2 dual inhibitor, in SNU216 and NCI-N87 cells.	saracatinib	0-11	epidermal growth factor receptor	Homo sapiens	50-54